Payment overview · 2025
General Payments
$141.03
7 reported records · 4 companies
Healthcare provider profile · identity verified
Harris Salim, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · KINGMAN, AZ · NPI 1144461591
Verified facts
What the public records show
CMS Open Payments records show Harris Salim, M.D. received $141.03 in general payments during 2025 across 7 reported records.
Amgen Inc. accounted for 39.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $55.68 | 39.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.54 | 29.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.02 | 17.7% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $18.79 | 13.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $141.03 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.54 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $40.73 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.02 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 588 | 185 |
| Lisinopril | Lisinopril | 446 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 294 | 80 |
| Metformin Hcl | Metformin Hcl | 252 | 82 |
| Simvastatin | Simvastatin | 215 | 74 |
| Losartan Potassium | Losartan Potassium | 209 | 66 |
| Potassium Chloride | Potassium Chloride | 206 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 197 | 70 |
| Furosemide | Furosemide | 186 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 60 |
| Prednisone | Prednisone | 171 | 126 |
| Gabapentin | Gabapentin | 162 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 47 |
| Trazodone Hcl | Trazodone Hcl | 131 | 50 |
| Ezetimibe | Ezetimibe | 108 | 40 |
| Omeprazole | Omeprazole | 108 | 37 |
| Eliquis | Apixaban | 106 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 103 | 34 |
| Jardiance | Empagliflozin | 99 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 49 |
| Carvedilol | Carvedilol | 91 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 90 | 72 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 13 |
| Azithromycin | Azithromycin | 78 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 24 |
| Cephalexin | Cephalexin | 64 | 53 |
| Mupirocin | Mupirocin | 63 | 47 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 44 |
| Ondansetron Odt | Ondansetron | 59 | 35 |
| Ozempic | Semaglutide | 56 | 20 |
| Donepezil Hcl | Donepezil Hcl | 55 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 18 |
| Myrbetriq | Mirabegron | 48 | 15 |
| Glipizide | Glipizide | 46 | 12 |
| Tramadol Hcl | Tramadol Hcl | 44 | 31 |
| Azelastine Hcl | Azelastine Hcl | 42 | 22 |
| Finasteride | Finasteride | 42 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 15 |
| Januvia | Sitagliptin Phosphate | 40 | 12 |
| Allopurinol | Allopurinol | 39 | 13 |
| Alprazolam | Alprazolam | 39 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 13 |
| Primidone | Primidone | 39 | suppressed |
| Cefdinir | Cefdinir | 38 | 34 |
| Methimazole | Methimazole | 38 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 29 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 27 |
| Warfarin Sodium | Warfarin Sodium | 33 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | 11 |
| Rybelsus | Semaglutide | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 23 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | 20 |
| Lorazepam | Lorazepam | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 23 |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Erythromycin | Erythromycin Base | 24 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Lactulose | Lactulose | 23 | 11 |
| Valsartan | Valsartan | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 22 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 19 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 13 |
| Klor-Con 10 | Potassium Chloride | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 12 | 12 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | 11 |
| Ramipril | Ramipril | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $141.03 · 7 records | Amgen Inc. | Assure WCD, EVENITY, MOUNJARO, OTEZLA, REPATHA, TRELEGY ELLIPTA, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error